Corpus overview


MeSH Disease

HGNC Genes

There are no HGNC terms in the subcorpus

SARS-CoV-2 proteins

There are no SARS-CoV-2 protein terms in the subcorpus


SARS-CoV-2 Proteins
    displaying 1 - 3 records in total 3
    records per page

    Characteristics and outcomes of 118,155 COVID-19 MESHD individuals with a history of cancer MESHD in the United States and Spain

    Authors: Elena Roel Mrs; Andrea Pistillo Mr; Martina Recalde Mrs; Anthony G Sena Mr; Sergio Fernandez-Bertolin Mr; Maria Aragon Mrs; Diana Puente Dr; Waheed-Ul-Rahman Ahmed Mr; Heba Alghoul Mr; Osaid Alser Mr; Thamir M Alshammari Dr; Carlos Areia Mr; Clair Blacketer Mrs; William Carter Mr; Paula Casajust Mrs; Aedin C Culhane Dr; Dalia Dawoud Dr; Frank DeFalco Mr; Scott L Duvall Dr; Thomas Falconer Mr; Asieh Golozar Dr; Mengchun Gong Mr; Laura Hester Dr; George Hripcsak Mr; Eng Hooi Tan Dr; Hokyun Jeon Mr; Jitendra Jonnagaddala Dr; Lana YH Lai Dr; Kristine E Lynch Dr; Michael E Matheny Mr; Daniel R Morales Dr; Karthik Natarajan Dr; Fredrik Nyberg Dr; Anna Ostropolets Mrs; Jose D Posada Dr; Albert Prats-Uribe Mr; Christian G Reich Dr; Donna Rivera Mrs; Lisa M Schilling Mrs; Isabelle Soerjomataram Dr; Karishma Shah Mrs; Nigam Shah Dr; Yang Shen Mr; Matthew Spotnitz Mr; Vignesh Subbian Dr; Marc A Suchard Dr; Annalisa Trama Dr; Lin Zhang Dr; Ying Zhang Dr; Patrick Ryan Dr; Daniel Prieto-Alhambra Dr; Kristin Kostka Mrs; Talita Duarte-Salles Dr

    doi:10.1101/2021.01.12.21249672 Date: 2021-01-15 Source: medRxiv

    PurposeWe aimed to describe the demographics, cancer MESHD subtypes, comorbidities and outcomes of patients with a history of cancer MESHD with COVID-19 MESHD from March to June 2020. Secondly, we compared patients hospitalized with COVID-19 MESHD to patients diagnosed with COVID-19 MESHD and patients hospitalized with influenza. MethodsWe conducted a cohort study using eight routinely-collected healthcare databases from Spain and the US, standardized to the Observational Medical Outcome Partnership common data model. Three cohorts of patients with a history of cancer MESHD were included: i) diagnosed with COVID-19 MESHD, ii) hospitalized with COVID-19 MESHD, and iii) hospitalized with influenza in 2017-2018. Patients were followed from index date to 30 days or death MESHD. We reported demographics, cancer MESHD subtypes, comorbidities, and 30-day outcomes. ResultsWe included 118,155 patients with a cancer MESHD history in the COVID-19 MESHD diagnosed and 41,939 in the COVID-19 MESHD hospitalized cohorts. The most frequent cancer MESHD subtypes were prostate and breast cancer MESHD (range: 5-19% and 1-14% in the diagnosed cohort, respectively). Hematological malignancies MESHD were also frequent, with non-Hodgkins lymphoma MESHD being among the 5 most common cancer MESHD subtypes in the diagnosed cohort. Overall, patients were more frequently aged above 65 years and had multiple comorbidities. Occurrence of death ranged from 8% to 14% and from 18% to 26% in the diagnosed and hospitalized COVID-19 MESHD cohorts, respectively. Patients hospitalized with influenza (n=242,960) had a similar distribution of cancer MESHD subtypes, sex, age and comorbidities but lower occurrence of adverse events. ConclusionPatients with a history of cancer MESHD and COVID-19 MESHD have advanced age, multiple comorbidities, and a high occurence of COVID-19 MESHD-related events. Additionaly, hematological malignancies MESHD were frequent in these patients.This observational study provides epidemiologic characteristics that can inform clinical care and future etiological studies.

    The impact of the coronavirus disease 2019 MESHD ( COVID-19 MESHD) outbreak on cancer practice in Japan: using an administrative database

    Authors: Hisashi Itoshima; Yuka Asami; Jung-ho Shin; Daisuke Takada; Tetsuji Morishita; Seiko Bun; Takuya Okuno; Susumu Kunisawa; Yuichi Imanaka

    doi:10.1101/2020.11.18.20233700 Date: 2020-11-18 Source: medRxiv

    Background: Recent researches reported the impact of the coronavirus disease 2019 MESHD (COVID - 19) pandemic on the clinical practice of specific type cancers MESHD. The aim of this study was to reveal the impact of the COVID-19 MESHD outbreak on the clinical practice of various cancers MESHD. Methods: We included hospitalized patients aged 18 years or older diagnosed between July 2018 and June 2020 with one of the top 12 most common cancers MESHD in Japan (colon/rectum, lung, gastric, breast MESHD, bladder & urinary tract, pancreas, non-Hodgkin lymphoma MESHD, liver, prostate, esophagus, uterus, and gallbladder & biliary tract) using Diagnostic Procedure Combination data, an administrative database in Japan. The intervention was defined April 2020 based on a declaration of emergency from Japanese government. The change volume of number of monthly admissions with each cancer MESHD was tested by interrupted time series (ITS) analysis, and monthly cases with radical surgery or chemotherapy for each cancer MESHD were descripted. Results: 403,344 cases were included during the study period. The most common cancer MESHD was colon MESHD/rectum (20.5%), followed by lung (17.5%). In almost cancer MESHD cases, the number of admissions decreased in May 2020. In particular, colorectal MESHD, lung, gastric, breast MESHD, uterine, or esophageal cancer MESHD cases decreased by over 10%. The number of admissions with surgery or chemotherapy decreased in colorectal MESHD, lung, gastric, breast MESHD, uterine, or esophageal cancer MESHD. ITS analysis indicated that cases with gastric or esophageal cancer MESHD were affected more than other type of cancer MESHD. Conclusions: The COVID-19 MESHD outbreak has a negative impact on the number of admission cases with cancer MESHD; the magnitude of impact varied by cancer MESHD diagnosis.

    Effect of hydroxychloroquine on COVID-19 MESHD prevention in cancer patients undergoing treatment: A structured summary of a study protocol for a randomised controlled trial.

    Authors: Abolghasem Allahyari; Hossein Rahimi; Majid Khadem-Rezaiyan; Zahra Mozaheb; Mohsen Seddigh-Shamsi; Alireza Bary; Mostafa Kamandi; Sajad Ataei Azimi; Saeed Eslami HasanbAbadi; Alireza Noferesti; Somayeh Sadat Shariatmaghani; Houshang Rafatpanah; Shohreh Khatami; Afshin Jabbar Imani; Hassan Mortazi; Mohammad Moeini Nodeh

    doi:10.21203/rs.3.pex-969/v1 Date: 2020-06-05 Source: ResearchSquare

    This is a multi-center, two-arm, parallel-group, triple-blind, phase 2-3 randomised controlled trial. All patients over the age of 15 from 5 types of cancer MESHD, acute lymphoid MESHD and myeloid leukemias MESHD, non-Hodgkin's lymphoma MESHD, breast and colon cancer MESHD will enter the study. Patients are randomly assigned to two groups. During two months of treatment, the two groups are treated with either hydroxychloroquine or placebo. Patients will be monitored for COVID-19 MESHD symptoms. The primary end point of the study is to investigate the incidence of COVID-19 MESHD in patients.Randomisation will be performed using randomly permuted blocks. The allocation ratio in two groups is 1:1. Participants, caregivers, outcome assessor and the data analyst are blinded to group assignment.The calculated total sample size is 60 patients, with 30 patients in each group. The trial began on April 14, 2020 and recruitment is ongoing. Recruitment is anticipated to be completed by June 14, 2020. This trial has been registered on the Iranian Registry of Clinical Trials (IRCT) with the registration number of IRCT20200405046958N1.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.